Jpmorgan Chase & Co. - Net Worth and Insider Trading

Jpmorgan Chase & Co. Net Worth

The estimated net worth of Jpmorgan Chase & Co. is at least $222 Million dollars as of 2024-11-13. Jpmorgan Chase & Co. is the of CanSino Biologics Inc and owns about 7,010,849 shares of CanSino Biologics Inc (HKSE:06185) stock worth over $222 Million. Details can be seen in Jpmorgan Chase & Co.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jpmorgan Chase & Co. has not made any transactions after 2023-07-25 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Jpmorgan Chase & Co.

Jpmorgan Chase & Co. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jpmorgan Chase & Co. owns 1 companies in total, including CanSino Biologics Inc (HKSE:06185) .

Click here to see the complete history of Jpmorgan Chase & Co.’s form 4 insider trades.

Insider Ownership Summary of Jpmorgan Chase & Co.

Ticker	Comapny	Transaction Date	Type of Owner
HKSE:06185	CanSino Biologics Inc	2023-07-25

Jpmorgan Chase & Co. Latest Holdings Summary

Jpmorgan Chase & Co. currently owns a total of 1 stock. Jpmorgan Chase & Co. owns 7,010,849 shares of CanSino Biologics Inc (HKSE:06185) as of July 25, 2023, with a value of $222 Million.

Latest Holdings of Jpmorgan Chase & Co.

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
HKSE:06185	CanSino Biologics Inc	2023-07-25	7,010,849	31.65	221,893,371

Holding Weightings of Jpmorgan Chase & Co.

Jpmorgan Chase & Co. Form 4 Trading Tracker

According to the SEC Form 4 filings, Jpmorgan Chase & Co. has made a total of 122 transactions in CanSino Biologics Inc (HKSE:06185) over the past 5 years, including 10 buys and 11 sells. The most-recent trade in CanSino Biologics Inc is the sale of 0 shares on July 25, 2023, which brought Jpmorgan Chase & Co. around $0.

Insider Trading History of Jpmorgan Chase & Co.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jpmorgan Chase & Co. Trading Performance

GuruFocus tracks the stock performance after each of Jpmorgan Chase & Co.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jpmorgan Chase & Co. is -24.58%. GuruFocus also compares Jpmorgan Chase & Co.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Jpmorgan Chase & Co. within 3 months outperforms 1 times out of 10 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jpmorgan Chase & Co.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jpmorgan Chase & Co.

Average Return

Average return per transaction

Outperforming Transactions

0 out of 10 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	-17.07
Relative Return to S&P 500(%)	-16.65

Jpmorgan Chase & Co. Ownership Network

Ownership Network List of Jpmorgan Chase & Co.

No Data

Ownership Network Relation of Jpmorgan Chase & Co.

Jpmorgan Chase & Co. Owned Company Details

What does CanSino Biologics Inc do?

Who are the key executives at CanSino Biologics Inc?

Jpmorgan Chase & Co. is the of CanSino Biologics Inc. Other key executives at CanSino Biologics Inc include 2201 Interest of corporation controlled by you The Capital Group Companies, Inc. , Citigroup Inc. , and 2201 Interest of corporation controlled by you The Goldman Sachs Group, Inc. .

CanSino Biologics Inc (HKSE:06185) Insider Trades Summary

Over the past 18 months, Jpmorgan Chase & Co. made 12 insider transaction in CanSino Biologics Inc (HKSE:06185) with a net purchase of 360,400. Other recent insider transactions involving CanSino Biologics Inc (HKSE:06185) include a net sale of 6,747,000 shares made by The Capital Group Companies, Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of CanSino Biologics Inc (HKSE:06185) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 7,168,200 shares of CanSino Biologics Inc (HKSE:06185) were sold and 781,600 shares were bought by its insiders, resulting in a net sale of 6,386,600 shares.

CanSino Biologics Inc (HKSE:06185)'s detailed insider trading history can be found in Insider Trading Tracker table.

CanSino Biologics Inc Insider Transactions

No Available Data

Jpmorgan Chase & Co. Mailing Address

Above is the net worth, insider trading, and ownership report for Jpmorgan Chase & Co.. Currently GuruFocus does not have mailing address information for Jpmorgan Chase & Co..

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.